GlassScriptPhysician profile
Gregory Egnaczyk
NPI 1174513733
$62,133.15
in general payments reported to CMS, 2019-2025
25 companies · $862 in 2025
The $862 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $799 · 2020: $2,820 · 2021: $20K · 2022: $30K · 2023: $7,537 · 2024: $623 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,845 · Food and Beverage: $2,588 · Travel and Lodging: $589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,845.00 |
| Food and Beverage | $2,588.14 |
| Travel and Lodging | $588.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $55,205.32 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Boston Scientific Corporation | $5,113.96 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $580.12 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $170.28 | 2022-2025 | Lifevest |
| Briohealth Solutions, INC. | $148.49 | 2025 | Briovad |
| Alnylam Pharmaceuticals INC. | $136.02 | 2019-2024 | Onpattro |
| Cvrx, INC. | $104.86 | 2025 | Barostim Neo System |
| Genzyme Corporation | $103.52 | 2025 | |
| Amgen INC. | $91.12 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $82.25 | 2021-2025 | Wainua, Tezspire |
| Merck Sharp & Dohme LLC | $70.06 | 2024-2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $61.93 | 2022-2025 | |
| Novo Nordisk INC | $51.37 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Kiniksa Pharmaceuticals International, Plc | $45.31 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $43.37 | 2025 | Assure Wcd |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $40.76 | 2024 | Impella |
| Pfizer INC. | $26.08 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.74 | 2024 | Jardiance |
| Chiesi USA, INC. | $15.62 | 2024 | Kengreal |
| Janssen Pharmaceuticals, INC | $12.64 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.51 | 2019 | |
| Nuwellis, INC. | $1.82 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Egnaczyk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.